The U.S. Food and Drug Administration (FDA) has authorized Philip Morris International to market its Zyn nicotine pouches, permitting the company to make claims that the product poses less harm than traditional cigarettes. This decision marks a significant step in the regulation of alternative nicotine products in the United States. The authorization was granted under the "Substantially Reduced Harm" (SRH) pathway. This means Philip Morris can now scientifically market Zyn with claims that individuals who completely switch from cigarettes to Zyn will reduce their exposure to a number of harmful chemicals. The FDA's review considered extensive scientific data submitted by the company. Despite the FDA's authorization, the move has drawn criticism from public health advocates. Concerns persist regarding the potential for increased youth use and addiction to nicotine products, even those marketed as less harmful. The debate highlights the ongoing challenge of balancing harm reduction strategies with preventing new generations from becoming addicted to nicotine.